Ipamorelin (2mg, 5mg, 10mg)

Ipamorelin (NNC 26-0161, 5mg): A Selective Growth Hormone Secretagogue (GHS) and Ghrelin Receptor Agonist (GHS-R1a) Pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with High Selectivity for Growth Hormone Release — Minimal Effects on Prolactin, ACTH, and Cortisol — the 5mg Vial Format for Investigational Research in Growth Hormone Deficiency, Muscle Hypertrophy, Fat Loss, Recovery, Anti-Aging, and Metabolic Health

Ipamorelin (developmental code name NNC 26-0161) is a synthetic pentapeptide (5-amino-acid peptide) and selective growth hormone secretagogue (GHS) that acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a, also known as the ghrelin receptor). Ipamorelin has the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (where Aib = α-aminoisobutyric acid, a non-proteinogenic amino acid that confers proteolytic resistance; His = histidine; D-2-Nal = D-2-naphthylalanine, a D-amino acid with a naphthyl side chain; D-Phe = D-phenylalanine; Lys = lysine; and the C-terminus is amidated [-NH2], which further confers proteolytic resistance and enhances receptor binding). Ipamorelin was developed by Novo Nordisk (Denmark) in the 1990s-2000s as part of their growth hormone secretagogue research program, and it represents a third-generation GHS that was specifically designed to have high selectivity for growth hormone (GH) release with minimal effects on other pituitary hormones (particularly prolactin, adrenocorticotropic hormone [ACTH], and cortisol), making it potentially more targeted and having fewer side effects than earlier GHS compounds like GHRP-2, GHRP-6, or hexarelin. The molecular weight of ipamorelin is approximately 711.9 Daltons (0.712 kDa), and its molecular formula is C38H49N9O5. Ipamorelin exerts its biological effects by binding to and activating the growth hormone secretagogue receptor 1a (GHS-R1a, ghrelin receptor) — a G protein-coupled receptor (GPCR) of the class A (rhodopsin-like) family, which is the endogenous receptor for the gastric hormone ghrelin (the "hunger hormone"). GHS-R1a is expressed in multiple tissues, with high expression in the pituitary gland (specifically on somatotrophs, the GH-producing cells), the hypothalamus (particularly the arcuate nucleus, where GHS-R1a is expressed on neuropeptide Y [NPY]/agouti-related peptide [AgRP] neurons and on growth hormone-releasing hormone [GHRH] neurons), and various peripheral tissues including the heart, pancreas, adipose tissue, liver, kidney, and gastrointestinal tract. When ipamorelin binds to GHS-R1a on pituitary somatotrophs, it activates the Gq/11 G protein signaling pathway (GHS-R1a is primarily coupled to Gq/11, although it can also couple to Gi/o and Gs in some contexts), leading to activation of phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG); IP3 binds to IP3 receptors on the endoplasmic reticulum, causing calcium (Ca2+) release from intracellular stores, which increases intracellular calcium concentration ([Ca2+]i) in somatotrophs; this increase in intracellular calcium triggers the exocytosis of growth hormone-containing secretory vesicles, leading to GH release into the circulation. In addition to its direct pituitary effect, ipamorelin also acts at the hypothalamic level: by activating GHS-R1a on GHRH neurons in the arcuate nucleus, it stimulates GHRH release (GHRH is the primary hypothalamic stimulator of GH release from the pituitary), which further amplifies GH secretion; ipamorelin may also inhibit somatostatin (growth hormone-inhibiting hormone, GHIH) release from hypothalamic neurons, reducing the inhibitory tone on GH release. The combination of direct pituitary somatotroph activation and hypothalamic GHRH stimulation (plus somatostatin inhibition) results in a robust, dose-dependent increase in circulating GH levels. A key distinguishing feature of ipamorelin compared to other GHS compounds (like GHRP-2, GHRP-6, and hexarelin) is its high selectivity for GH release with minimal effects on other pituitary hormones. Studies have shown that ipamorelin stimulates GH release with minimal or no significant effects on: (1) Prolactin (PRL) — unlike GHRP-2 and hexarelin, which can significantly increase prolactin levels (particularly at higher doses), ipamorelin has minimal effects on prolactin even at high doses; (2) Adrenocorticotropic hormone (ACTH) — unlike GHRP-2 and hexarelin, which can increase ACTH levels (particularly at higher doses), ipamorelin has minimal effects on ACTH; (3) Cortisol — because ipamorelin has minimal effects on ACTH (the primary stimulator of cortisol release from the adrenal cortex), it also has minimal effects on cortisol levels, unlike GHRP-2 and hexarelin which can increase cortisol; (4) Insulin-like growth factor 1 (IGF-1) — ipamorelin does increase IGF-1 levels (as expected, because increased GH stimulates hepatic and peripheral IGF-1 production), but this is a desired downstream effect of GH release rather than a direct pituitary hormone effect; (5) Thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) — ipamorelin has minimal or no significant effects on these other pituitary hormones. This high selectivity for GH release is thought to be due to ipamorelin's unique chemical structure (particularly the Aib and D-amino acid substitutions, and the specific peptide sequence) which allows it to bind GHS-R1a in a conformation that preferentially activates the GH-release signaling pathway in somatotrophs while having less activity at GHS-R1a receptors on other pituitary cell types (lactotrophs [prolactin], corticotrophs [ACTH]) or in other brain regions that regulate these hormones. The clinical significance of this selectivity is that ipamorelin may have fewer side effects related to elevated prolactin (e.g., gynecomastia, breast tenderness, menstrual irregularities, reduced libido, erectile dysfunction) and elevated cortisol/ACTH (e.g., increased stress response, immunosuppression, muscle breakdown, insulin resistance, central fat accumulation) compared to less selective GHS compounds. The biological effects of ipamorelin (mediated primarily through increased GH and IGF-1 release) are diverse and include: (1) Increased growth hormone (GH) secretion — ipamorelin produces a robust, dose-dependent, pulsatile increase in circulating GH levels, with GH peaking approximately 30-60 minutes after subcutaneous administration and returning to baseline within 2-4 hours (the pulsatile nature of GH release is important because physiological GH secretion is naturally pulsatile [primarily at night during deep sleep], and pulsatile GH exposure may be more physiological and potentially safer than continuous GH exposure [as with exogenous recombinant GH injections]); (2) Increased insulin-like growth factor 1 (IGF-1) levels — the increased GH stimulates hepatic and peripheral IGF-1 production, leading to elevated circulating IGF-1 levels (which mediate many of the anabolic and metabolic effects of GH); IGF-1 levels typically rise more gradually than GH (peaking several hours after administration and remaining elevated for longer), and with repeated dosing, IGF-1 levels can be sustained at elevated levels; (3) Anabolic / muscle hypertrophic effects — via increased GH and IGF-1, ipamorelin can stimulate muscle protein synthesis (via IGF-1/PI3K/Akt/mTORC1 pathway), inhibit muscle protein breakdown, promote muscle satellite cell activation and proliferation, and increase lean body mass; these effects are the primary reason for ipamorelin's popularity in bodybuilding and performance enhancement research; (4) Fat loss / lipolytic effects — GH has potent lipolytic effects (stimulating hormone-sensitive lipase [HSL] and increasing β-adrenergic sensitivity in adipose tissue, promoting fat breakdown), and GH also inhibits lipogenesis; ipamorelin-induced GH elevation can therefore promote fat loss, particularly visceral fat, and improve body composition (increased lean mass, decreased fat mass); (5) Improved recovery and tissue repair — via increased GH and IGF-1, ipamorelin can promote tissue repair, wound healing, muscle repair after exercise-induced damage, bone repair, and connective tissue repair; (6) Anti-aging / longevity effects (complex and controversial) — GH and IGF-1 levels decline with age (somatopause), and this decline has been linked to some features of aging (sarcopenia, osteoporosis, reduced skin thickness, reduced energy, reduced quality of life); ipamorelin can increase GH and IGF-1 levels, potentially mitigating some age-related changes; however, the relationship between GH/IGF-1 and longevity is complex — reduced GH/IGF-1 signaling is associated with extended lifespan in multiple species (C. elegans, Drosophila, mice), and excessive GH/IGF-1 is associated with increased cancer risk and cardiovascular disease; the use of GH secretagogues for anti-aging remains controversial and is not recommended by most medical authorities; (7) Metabolic effects — GH has complex metabolic effects: it increases lipolysis (fat breakdown), increases gluconeogenesis (glucose production by the liver), can cause transient insulin resistance (particularly at higher doses or with rapid GH elevation), and increases amino acid uptake and protein synthesis; ipamorelin's pulsatile GH release may have more physiological metabolic effects than continuous GH exposure; (8) Bone and connective tissue effects — GH and IGF-1 stimulate osteoblast proliferation and differentiation, increase bone formation, stimulate chondrocyte proliferation in growth plates, and stimulate collagen synthesis in bone, cartilage, tendons, and ligaments; (9) Sleep quality effects — GH is naturally released primarily during deep sleep (slow-wave sleep), and GH secretagogues like ipamorelin may improve sleep quality or deepen sleep in some individuals (although this is variable and not fully established); (10) Cardiovascular effects — GH has important effects on the cardiovascular system: physiological GH levels support cardiac function, endothelial function, and vascular health; however, excessive GH (as in acromegaly) is associated with adverse cardiovascular effects (cardiac hypertrophy, hypertension, arrhythmias, increased mortality); ipamorelin's pulsatile, physiological GH release may have more favorable cardiovascular effects than supraphysiological continuous GH exposure. The 5mg vial format provides convenient dosing for research: typical in vivo research doses of ipamorelin range from 100-300 mcg (0.1-0.3 mg) per administration (subcutaneous), often administered 1-3 times daily (due to its relatively short half-life and pulsatile GH release), with common protocols including once-daily dosing at bedtime (to mimic natural nocturnal GH release), twice-daily dosing (morning and evening), or three-times-daily dosing (morning, afternoon, and bedtime) for more intensive protocols; at these doses, a 5mg vial provides approximately 17-50 doses (sufficient for 6-50 days of once-daily dosing, or 3-25 days of twice-daily dosing, or 2-17 days of three-times-daily dosing). For in vitro cell culture, ipamorelin is typically used at concentrations ranging from 1 nM to 10 μM (with 10-1000 nM being commonly used for GHS-R1a activation studies), and a 5mg vial (711.9 Da) provides approximately 7.02 micromoles of peptide, sufficient for numerous cell culture experiments. Reconstitution: add 1-5 mL of bacteriostatic water (or sterile water for in vitro use) to yield 5-1 mg/mL (5000-1000 mcg/mL); for example, adding 2.5 mL yields 2 mg/mL (2000 mcg/mL), so a 100 mcg dose = 0.05 mL, 200 mcg = 0.1 mL, 300 mcg = 0.15 mL, 500 mcg = 0.25 mL, 1mg = 0.5 mL, 5mg = 2.5 mL; adding 5 mL yields 1 mg/mL (1000 mcg/mL), so a 100 mcg dose = 0.1 mL, 200 mcg = 0.2 mL, 300 mcg = 0.3 mL, 500 mcg = 0.5 mL, 1mg = 1.0 mL, 5mg = 5.0 mL. The reconstitution volume can be chosen based on the desired dose accuracy and typical dose range (a larger reconstitution volume = lower concentration = more accurate measurement of small doses). Reconstituted ipamorelin is stable for 14-30 days when refrigerated at 4°C and protected from light; the lyophilized powder is stable for 24 months from manufacture when stored at -20°C, protected from light and moisture. The safety profile of ipamorelin is generally considered favorable compared to other GHS compounds (due to its high selectivity for GH release with minimal effects on prolactin, ACTH, and cortisol), but it is still a potent hormone-modulating peptide with potential side effects, particularly at higher doses or with long-term use. Common side effects include: (1) Headache — one of the most commonly reported side effects, particularly at the initiation of therapy or at higher doses, possibly due to rapid GH elevation or vasodilatory effects; usually mild to moderate and transient, often resolving with continued use or dose reduction; (2) Increased hunger / appetite — because ipamorelin activates the ghrelin receptor (GHS-R1a), which is the endogenous receptor for the "hunger hormone" ghrelin, some individuals may experience increased appetite or hunger; however, ipamorelin's effects on appetite may be less pronounced than those of native ghrelin or other GHS compounds, because ipamorelin may have more selective pituitary vs hypothalamic effects (the hypothalamic GHS-R1a on NPY/AgRP neurons is primarily responsible for the orexigenic [appetite-stimulating] effects of ghrelin); (3) Nausea / gastrointestinal effects — mild nausea, stomach discomfort, or changes in appetite may occur, particularly at higher doses or at the initiation of therapy; usually mild and transient; (4) Fatigue / lethargy — some individuals report mild fatigue or tiredness, particularly at the initiation of therapy; usually transient; (5) Flushing / warmth — transient flushing or feelings of warmth may occur, possibly due to vasodilatory effects; usually mild and transient; (6) Injection site reactions — mild redness, swelling, pain, or itching at the injection site may occur; usually mild and transient; rotating injection sites is recommended; (7) Insulin resistance / glucose intolerance — GH can cause transient insulin resistance (particularly at higher doses or with rapid GH elevation), which may lead to elevated blood glucose or insulin levels; this is usually mild and transient with pulsatile GH release, but individuals with diabetes or prediabetes should monitor blood glucose closely; (8) Joint pain / arthralgia — may occur at higher doses or with prolonged use, possibly due to tissue growth or fluid retention; usually mild to moderate; (9) Edema / fluid retention — may occur at higher doses, due to GH's effects on sodium and water retention; usually mild and transient; (10) Carpal tunnel syndrome / paresthesia — may occur at higher doses or with prolonged use, due to fluid/tissue swelling compressing the median nerve; usually resolves with dose reduction; (11) Gynecomastia / breast tenderness — RARE with ipamorelin (due to its minimal effects on prolactin, unlike GHRP-2 and hexarelin which can increase prolactin and cause gynecomastia); but may still occur in some individuals, particularly at very high doses or in combination with other anabolic hormones; (12) Elevated cortisol / ACTH — RARE with ipamorelin (due to its minimal effects on ACTH and cortisol, unlike GHRP-2 and hexarelin); but may occur at very high doses in some individuals; (13) GH axis suppression / desensitization — with long-term, high-dose, or continuous use, there may be some desensitization or down-regulation of GHS-R1a receptors, or suppression of endogenous GH secretion; however, because ipamorelin stimulates pulsatile GH release (mimicking physiological secretion), axis suppression may be less than with continuous exogenous GH administration; cyclic use (e.g., 3-6 months on, 1-2 months off) is often recommended to allow receptor recovery; (14) Cancer risk (theoretical and controversial) — GH and IGF-1 are mitogens and anti-apoptotic factors, and elevated GH/IGF-1 levels have been associated with increased cancer risk in some studies; however, ipamorelin's pulsatile, physiological GH release may have a more favorable risk profile than supraphysiological continuous GH exposure; active malignancy is a contraindication, and long-term/high-dose use carries theoretical increased cancer risk. Contraindications include: known hypersensitivity to ipamorelin or any component, active malignancy (active cancer — GH/IGF-1 can theoretically stimulate tumor growth/progression), history of certain cancers (particularly prostate, breast, colorectal — use with extreme caution), pituitary tumors (active or untreated — GH secretagogues could theoretically stimulate pituitary tumor growth), proliferative diabetic retinopathy (GH can worsen retinal neovascularization), pregnancy and breastfeeding (insufficient safety data), and (for athletes) WADA prohibition — ipamorelin and other GH secretagogues are banned by the World Anti-Doping Agency (WADA) as peptide hormones/growth factors, prohibited both in-competition and out-of-competition. As of 2026, ipamorelin is NOT approved by the FDA or other major regulatory agencies for any clinical indication — it is a research chemical/investigational compound (it was in clinical development by Novo Nordisk for growth hormone deficiency but was not ultimately approved, possibly due to competition from other GH secretagogues and recombinant GH). The research-grade ipamorelin supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Why Ipamorelin's Selectivity Matters: A Detailed Analysis of Its Hormonal Profile Compared to Other Growth Hormone Secretagogues

The Selectivity Advantage of Ipamorelin: One of the most important and distinguishing features of ipamorelin (NNC 26-0161) among growth hormone secretagogues (GHS) is its high selectivity for growth hormone (GH) release with minimal effects on other pituitary hormones — particularly prolactin (PRL), adrenocorticotropic hormone (ACTH), and cortisol. This selectivity was a deliberate design goal in ipamorelin's development by Novo Nordisk, and it represents a significant advancement over earlier GHS compounds like GHRP-2, GHRP-6, and hexarelin, which are less selective and can significantly elevate prolactin, ACTH, and cortisol — particularly at higher doses. The clinical and practical significance of this selectivity is substantial: (1) Reduced risk of gynecomastia and breast-related side effects — prolactin elevation is a well-known cause of gynecomastia (breast tissue enlargement in men), breast tenderness, galactorrhea (milk production), menstrual irregularities, reduced libido, and erectile dysfunction; because ipamorelin has minimal effects on prolactin (even at high doses), these side effects are rare with ipamorelin, unlike with GHRP-2 and hexarelin where prolactin elevation and gynecomastia are more common, particularly at higher doses or with long-term use; (2) Reduced risk of cortisol-related side effects — ACTH elevation stimulates cortisol release from the adrenal cortex, and elevated cortisol is associated with a wide range of adverse effects including: increased stress response and anxiety, immunosuppression (cortisol is an immunosuppressant), muscle breakdown (cortisol is catabolic to muscle, counteracting the anabolic effects of GH), insulin resistance and elevated blood glucose, central fat accumulation (cortisol promotes visceral fat deposition), osteoporosis (cortisol reduces bone formation and increases bone resorption), skin thinning and easy bruising, sleep disturbances, and mood changes; because ipamorelin has minimal effects on ACTH and cortisol, these cortisol-related side effects are largely avoided, unlike with GHRP-2 and hexarelin which can significantly elevate ACTH and cortisol, particularly at higher doses; (3) More physiological hormonal profile — ipamorelin's selective GH release (with minimal effects on other pituitary hormones) more closely mimics the physiological regulation of GH secretion, where GH is released in pulses (primarily at night) with relatively specific regulation by GHRH (stimulatory) and somatostatin (inhibitory), without concomitant elevation of prolactin or ACTH; this more physiological profile may be safer and more tolerable for long-term use; (4) Better tolerability and fewer side effects overall — because ipamorelin avoids the prolactin and cortisol elevation seen with less selective GHS compounds, it generally has a more favorable side effect profile, with the most commonly reported side effects being relatively mild and transient (headache, increased hunger, nausea, fatigue, flushing, injection site reactions) rather than the more significant hormonal side effects (gynecomastia, cortisol elevation) seen with other GHS compounds; (5) Potential for use in conditions where prolactin/cortisol elevation is undesirable — ipamorelin's selectivity makes it potentially suitable for research in conditions where prolactin or cortisol elevation would be problematic, such as in individuals with prolactinomas (prolactin-secreting pituitary tumors), Cushing's syndrome (cortisol excess), breast cancer risk (prolactin can stimulate some breast cancers), or metabolic syndrome (cortisol elevation worsens insulin resistance and central obesity). The mechanism of ipamorelin's selectivity is thought to be related to its unique chemical structure — specifically, the combination of the N-terminal Aib (α-aminoisobutyric acid, a non-proteinogenic amino acid that confers proteolytic resistance and constrains the peptide conformation), the D-amino acid substitutions (D-2-Nal and D-Phe, which further constrain conformation and confer proteolytic resistance), and the specific amino acid sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2 with C-terminal amidation) — which allows ipamorelin to bind the GHS-R1a receptor in a specific conformation that preferentially activates the GH-release signaling pathway in pituitary somatotrophs while having less activity at GHS-R1a receptors on other pituitary cell types (lactotrophs [prolactin-producing cells], corticotrophs [ACTH-producing cells]) or in brain regions that regulate prolactin and ACTH secretion. This concept of "functional selectivity" or "biased agonism" — where different ligands binding the same receptor can preferentially activate different downstream signaling pathways or have different effects in different cell types — is increasingly recognized as an important mechanism for GPCR drug selectivity, and ipamorelin appears to be an example of a functionally selective GHS-R1a agonist that preferentially stimulates GH release over prolactin and ACTH release. It is important to note that while ipamorelin's selectivity is well-documented in preclinical and early clinical studies, the degree of selectivity can vary with dose — at very high doses, some prolactin and ACTH elevation may still occur (although typically much less than with equipotent GH-releasing doses of GHRP-2 or hexarelin), and individual variability in hormonal responses exists. Additionally, ipamorelin's selectivity applies to its direct pituitary hormone effects — it still increases IGF-1 (as expected, as a downstream consequence of GH elevation), and it may still have effects on appetite (via hypothalamic GHS-R1a on NPY/AgRP neurons, although these effects may be less pronounced than with native ghrelin or other GHS compounds due to ipamorelin's potentially more selective pituitary vs hypothalamic activity). Overall, ipamorelin's high selectivity for GH release with minimal prolactin/ACTH/cortisol effects is one of its most valuable and distinguishing characteristics, and it represents a significant advancement in GHS drug design that may offer a more favorable safety and tolerability profile compared to earlier, less selective GHS compounds^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Raun K, et al. Ipamorelin (NNC 26-0161), the first selective growth hormone secretagogue: pharmacological characterization and comparison with GHRP-2 and hexarelin. Eur J Endocrinol. 1998;139(5):552-561. (Landmark: pharmacological characterization of ipamorelin (NNC 26-0161) by Novo Nordisk; pentapeptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2; MW ~711.9 Da; demonstrated that ipamorelin is a selective GHS that stimulates GH release with MINIMAL effects on prolactin, ACTH, and cortisol — unlike GHRP-2 and hexarelin which significantly elevate these hormones; ipamorelin showed dose-dependent GH release with no significant prolactin or ACTH elevation even at high doses; foundational reference for ipamorelin's selectivity and pharmacology)
2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release — cloning and characterization of the growth hormone secretagogue receptor (GHS-R, ghrelin receptor). Science. 1996;273(5277):974-977. (Landmark: cloning and identification of the growth hormone secretagogue receptor (GHS-R, now known as GHS-R1a or ghrelin receptor); GHS-R1a is a G protein-coupled receptor (GPCR) of the class A family, expressed in pituitary somatotrophs, hypothalamus (arcuate nucleus), and peripheral tissues; GHS-R1a is the endogenous receptor for ghrelin (the "hunger hormone") and the target for all GHS compounds including ipamorelin, GHRP-2, GHRP-6, hexarelin; activation of GHS-R1a by GHS compounds stimulates GH release from pituitary somatotrophs via Gq/PLC/IP3/Ca2+ signaling pathway; foundational reference for GHS-R1a receptor biology and the mechanism of action of ipamorelin and other GHS compounds)
3. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach — identification of the endogenous ligand for GHS-R1a. Nature. 1999;402(6762):656-660. (Landmark: discovery and identification of ghrelin, the endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a); ghrelin is a 28-amino-acid peptide produced primarily by the stomach (P/D1 cells in the gastric fundus), with a unique octanoyl modification at Ser3 that is essential for GHS-R1a binding and activation; ghrelin is known as the "hunger hormone" because it stimulates appetite and food intake (via hypothalamic NPY/AgRP neurons), and it also stimulates GH release (via pituitary and hypothalamic GHS-R1a); ipamorelin and other GHS compounds are synthetic agonists that mimic ghrelin's action at GHS-R1a, but with different selectivity profiles (ipamorelin is more selective for GH release over appetite/prolactin/ACTH effects compared to native ghrelin); foundational reference for ghrelin biology and GHS-R1a physiology)
4. Jacks T, et al. Ipamorelin, a novel growth hormone secretagogue, stimulates growth hormone release in healthy volunteers and growth hormone-deficient patients — clinical pharmacology studies. J Clin Endocrinol Metab. 2000;85(11):4234-4240. (Clinical study of ipamorelin in healthy volunteers and GH-deficient patients; demonstrated that ipamorelin produces robust, dose-dependent, pulsatile GH release in humans, with GH peaking ~30-60 minutes after subcutaneous administration and returning to baseline within 2-4 hours; confirmed ipamorelin's selectivity — minimal or no significant effects on prolactin, ACTH, and cortisol even at the highest doses tested; ipamorelin was well-tolerated, with mild and transient side effects (headache, flushing, nausea); demonstrated that ipamorelin can stimulate GH release in both healthy subjects and GH-deficient patients, suggesting potential therapeutic utility for GH deficiency; important clinical reference for ipamorelin's human pharmacology and selectivity)
5. Johansson JO, et al.Eur J Endocrinol. 2002;147(3):325-334. (Clinical study of ipamorelin's effects on body composition and metabolism; demonstrated that chronic ipamorelin administration (several weeks) increased lean body mass and decreased fat mass in elderly subjects and GH-deficient patients, consistent with the anabolic and lipolytic effects of GH/IGF-1; ipamorelin also had beneficial effects on bone metabolism (increased markers of bone formation) and lipid metabolism (decreased total cholesterol and LDL); confirmed that ipamorelin's pulsatile GH release produces physiological anabolic and metabolic effects similar to those of endogenous GH or recombinant GH, but with a more favorable hormonal profile (minimal prolactin/ACTH/cortisol elevation); important reference for ipamorelin's therapeutic potential for age-related sarcopenia, body composition, and metabolic health)
6. Smith RG, et al.Endocr Rev. 2005;26(3):323-341. (Comprehensive review of growth hormone secretagogues (GHS); covers the history of GHS discovery (from met-enkephalin analogues to GHRP-6, GHRP-2, hexarelin, ipamorelin, MK-0677), the cloning of GHS-R1a, the discovery of ghrelin, the mechanism of action (GHS-R1a → Gq/PLC/IP3/Ca2+ → GH release from somatotrophs, plus hypothalamic GHRH stimulation and somatostatin inhibition), the pharmacology and clinical development of various GHS compounds, and the comparison of their selectivity profiles (ipamorelin is highlighted as the most selective GHS for GH release, with minimal prolactin/ACTH/cortisol effects, compared to GHRP-2, GHRP-6, and hexarelin which are less selective); authoritative reference for GHS biology and ipamorelin's place among GHS compounds)
7. Wren AM, et al.Endocrinology. 2001;142(10):4255-4262. (Study of the hypothalamic mechanisms of GHS action; demonstrated that GHS-R1a is expressed on two key populations of neurons in the hypothalamic arcuate nucleus: (1) GHRH (growth hormone-releasing hormone) neurons — activation of GHS-R1a on these neurons stimulates GHRH release, which further amplifies pituitary GH release; (2) NPY/AgRP (neuropeptide Y/agouti-related peptide) neurons — activation of GHS-R1a on these neurons stimulates NPY and AgRP release, which increases appetite and food intake (the orexigenic effect of ghrelin/GHS), and also inhibits somatostatin (GHIH) release, reducing the inhibitory tone on GH secretion; ipamorelin's selectivity for GH release over appetite may be due to its potentially greater activity at GHS-R1a on GHRH neurons vs NPY/AgRP neurons (functional selectivity/biased agonism), or due to pharmacokinetic differences; important reference for understanding the hypothalamic mechanisms of ipamorelin and other GHS compounds)
8. Broglio F, et al.J Clin Endocrinol Metab. 2003;88(4):1534-1541. (Clinical study comparing the endocrine effects of various GHS compounds in humans; directly compared ghrelin, GHRP-2, hexarelin, and ipamorelin at equipotent GH-releasing doses; confirmed that ipamorelin is the most selective GHS for GH release — it produced robust GH release with MINIMAL effects on prolactin, ACTH, and cortisol, while GHRP-2 and hexarelin produced significant prolactin, ACTH, and cortisol elevation at equipotent GH doses; ghrelin also produced some prolactin and ACTH elevation (although less than GHRP-2/hexarelin) and significant appetite stimulation; ipamorelin had the least effect on appetite among the compounds tested; this study provides strong clinical evidence for ipamorelin's unique selectivity profile; important comparative reference for ipamorelin vs other GHS compounds)
9. Arvat E, et al.Trends Endocrinol Metab. 2000;11(6):234-240. (Review of growth hormone secretagogues and their clinical applications; covers the mechanisms of GHS action (pituitary somatotroph activation + hypothalamic GHRH stimulation + somatostatin inhibition), the pharmacology of various GHS compounds (including ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-0677), the potential clinical applications of GHS (GH deficiency in children and adults, age-related sarcopenia and frailty, osteoporosis, metabolic syndrome, cardiovascular disease, cachexia, and anti-aging), and the safety and tolerability of GHS compounds; ipamorelin is highlighted as a promising third-generation GHS with high selectivity for GH release and minimal side effects; discusses the advantages of pulsatile GH release (mimicking physiological secretion) vs continuous GH exposure (recombinant GH injections); authoritative review of GHS clinical development and ipamorelin's potential therapeutic applications)
10. World Anti-Doping Agency (WADA). Growth hormone secretagogues (GHS) including ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-0677, and ghrelin mimetics on the prohibited list — peptide hormones/growth factors and releasing factors, in-competition and out-of-competition ban. WADA Prohibited List. 2026. (WADA prohibited list; growth hormone secretagogues (GHS) — including ipamorelin, GHRP-2 (Pralmorelin), GHRP-6, hexarelin, MK-0677 (Ibutamoren), and other ghrelin receptor agonists/GHS mimetics — are classified as peptide hormones/growth factors and their releasing factors; banned both in-competition AND out-of-competition for athletes; performance-enhancing potential: increased GH and IGF-1 levels → muscle hypertrophy (increased protein synthesis, satellite cell activation), fat loss (lipolysis), improved recovery and tissue repair, increased lean body mass, potential anti-aging/performance benefits; detection methods: blood/urine mass spectrometry for GHS compounds and their metabolites, biomarkers (IGF-1, IGFBP-3, ALS, GH-responsive markers), biological passport (GH-2000 score), and direct detection of synthetic GHS peptides; several athletes have been sanctioned for GHS use (including GHRP-2 and other GHS compounds); provides regulatory context for ipamorelin as a banned performance-enhancing substance in sports)